Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

D R Jayne1, H Chapel, D Adu

  • 1Division of Renal Medicine, St George's Hospital Medical School and Renal Unit, St Helier Hospital, London. djayne@sghms.ac.uk

QJM : Monthly Journal of the Association of Physicians
|June 30, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of spirituality and identity formation in personal recovery from traumatic brain injury: A qualitative analysis through the personal experiences of survivors.

Neuropsychological rehabilitation·2023
Same author

Response to: 'Renal biopsies should be performed whenever treatment strategies depend on renal involvement' by Chemouny <i>et al</i>.

Annals of the rheumatic diseases·2017
Same author

Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016
Same author

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Annals of the rheumatic diseases·2016
Same author

Incidence, care quality and outcomes of patients with acute kidney injury in admitted hospital care.

QJM : monthly journal of the Association of Physicians·2016
Same author

Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers.

Gut·2015

Intravenous immunoglobulin (IVIg) offers a temporary benefit for anti-neutrophil cytoplasm antibody-associated systemic vasculitis (AASV) but lacks long-term efficacy. While IVIg showed initial promise in reducing disease activity, its effects diminished after three months, with frequent mild side effects observed.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Trials

Background:

  • Anti-neutrophil cytoplasm antibody-associated systemic vasculitis (AASV) is a serious autoimmune condition.
  • Conventional immunosuppressive agents carry significant toxicity.
  • Intravenous immunoglobulin (IVIg) presents a potential alternative treatment option for AASV.

Purpose of the Study:

  • To evaluate the efficacy of a single course of IVIg in patients with persistent AASV.
  • To assess IVIg's impact on disease activity, C-reactive protein (CRP), and anti-neutrophil cytoplasm antibody (ANCA) levels.
  • To compare IVIg's safety profile against placebo in AASV patients.

Main Methods:

  • A randomized, placebo-controlled trial involving 34 patients with persistent AASV.

Related Experiment Videos

  • Patients received either a single course of IVIg (2 g/kg) or placebo.
  • Disease activity was assessed using the Birmingham Vasculitis Activity Score (BVAS), CRP, and ANCA levels up to 12 months.

    • Main Results:

    • A significantly higher treatment response rate (50% BVAS reduction) was observed in the IVIg group compared to placebo at 3 months (14/17 vs. 6/17).
    • IVIg led to greater reductions in CRP at 2 weeks and 1 month post-infusion.
    • No sustained differences in disease activity or CRP levels were noted beyond 3 months; mild adverse events were more frequent in the IVIg group.

    Conclusions:

    • A single IVIg course provides a transient reduction in disease activity for persistent AASV.
    • The therapeutic effect of IVIg in AASV is not maintained long-term.
    • IVIg can be considered an alternative treatment for AASV after standard therapies, with careful monitoring for side effects.